Business Description
Fisher & Paykel Healthcare Corp Ltd
ISIN : NZFAPE0001S2
Share Class Description:
FRA:FPLB: Ordinary SharesTotal Employee Number:
7,434Compare
Compare
Traded in other countries / regions
FPH.New ZealandFPH.AustraliaFSPKF.USAFPLB.Germany IPO Date
2020-06-05Description
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.16 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.18 | |||||
Interest Coverage | 46.39 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 20.89 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.7 | |||||
3-Year EBITDA Growth Rate | 22.1 | |||||
3-Year EPS without NRI Growth Rate | 22.6 | |||||
3-Year FCF Growth Rate | 158.2 | |||||
3-Year Book Growth Rate | 6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.96 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.42 | |||||
9-Day RSI | 57.62 | |||||
14-Day RSI | 56.67 | |||||
3-1 Month Momentum % | 2.73 | |||||
6-1 Month Momentum % | 3.3 | |||||
12-1 Month Momentum % | 1.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.31 | |||||
Quick Ratio | 1.66 | |||||
Cash Ratio | 0.93 | |||||
Days Inventory | 146.17 | |||||
Days Sales Outstanding | 45.78 | |||||
Days Payable | 54.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.37 | |||||
Dividend Payout Ratio | 0.54 | |||||
3-Year Dividend Growth Rate | -0.8 | |||||
Forward Dividend Yield % | 1.37 | |||||
5-Year Yield-on-Cost % | 1.75 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 1.35 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.69 | |||||
Operating Margin % | 20.7 | |||||
Net Margin % | 20.3 | |||||
EBITDA Margin % | 34.67 | |||||
FCF Margin % | 20.29 | |||||
OCF Margin % | 28.76 | |||||
ROE % | 23.46 | |||||
ROA % | 17.49 | |||||
ROIC % | 17.23 | |||||
3-Year ROIIC % | 74.72 | |||||
ROC (Joel Greenblatt) % | 40.18 | |||||
ROCE % | 29.32 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 48.49 | |||||
Forward PE Ratio | 40.17 | |||||
PE Ratio without NRI | 48.49 | |||||
Shiller PE Ratio | 64.14 | |||||
Price-to-Owner-Earnings | 50.59 | |||||
PS Ratio | 9.84 | |||||
PB Ratio | 10.67 | |||||
Price-to-Tangible-Book | 11.24 | |||||
Price-to-Free-Cash-Flow | 48.55 | |||||
Price-to-Operating-Cash-Flow | 34.24 | |||||
EV-to-EBIT | 35.31 | |||||
EV-to-Forward-EBIT | 30.55 | |||||
EV-to-EBITDA | 28.32 | |||||
EV-to-Forward-EBITDA | 22.49 | |||||
EV-to-Revenue | 9.82 | |||||
EV-to-Forward-Revenue | 8.72 | |||||
EV-to-FCF | 47.58 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 5.62 | |||||
Price-to-Median-PS-Value | 1.1 | |||||
Price-to-Graham-Number | 4.96 | |||||
| Price-to-Net-Current-Asset-Value | 56.18 | |||||
Earnings Yield (Greenblatt) % | 2.83 | |||||
FCF Yield % | 2.03 | |||||
Forward Rate of Return (Yacktman) % | 0.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fisher & Paykel Healthcare Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,162.558 | ||
| EPS (TTM) (€) | 0.399 | ||
| Beta | 0.7992 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 1.01 | ||
| Volatility % | 14.92 | ||
| 14-Day RSI | 56.67 | ||
| 14-Day ATR (€) | 0.31577 | ||
| 20-Day SMA (€) | 18.785 | ||
| 12-1 Month Momentum % | 1.62 | ||
| 52-Week Range (€) | 16 - 20.6 | ||
| Shares Outstanding (Mil) | 587.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fisher & Paykel Healthcare Corp Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fisher & Paykel Healthcare Corp Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-26 10:00 | In 150 days | ||
| Second quarter earnings results for 2027 | 2026-11-26 09:00 | In 150 days | ||
| General meeting for 2026 | 2026-08-21 14:00 | In 53 days | ||
| NZD 0.330000 Cash Dividend | 2026-06-22 | 18.40 (+0.00%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-26 10:00 | 16.70 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-26 | 16.70 (+0.00%) | ||
| Annual report for 2026 | 2026-05-25 | 16.90 (+0.00%) | ||
| NZD 0.190000 Cash Dividend | 2025-12-03 | 18.40 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2025-11-26 10:00 | 17.50 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2025-11-26 09:00 | 17.50 (+0.00%) |
Show
Entries
Fisher & Paykel Healthcare Corp Ltd Frequently Asked Questions
What is Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB)'s stock price today?
The current price of FRA:FPLB is €19.10. The 52 week high of FRA:FPLB is €20.60 and 52 week low is €16.00.
When is next earnings date of Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB)?
The next earnings date of Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB) is 2026-11-26 Est..
Does Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB) pay dividends? If so, how much?
The Dividend Yield %  of Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB) is 1.37% (As of Today), Highest Dividend Payout Ratio of Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB) was 1.81. The lowest was 0.35. And the median was 0.61. The  Forward Dividend Yield % of Fisher & Paykel Healthcare Corp Ltd(FRA:FPLB) is 1.37%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Fisher & Paykel Healthcare Corp Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers